Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials

Current Hematologic Malignancy Reports

Volumn 8, Issue 1, 2013, Pages 1-6

  Brown, Jennifer R ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

BTK; CLL; Ibrutinib; Kinase; Lymphocytosis; PCI32765

Indexed keywords

ALEMTUZUMAB; BRUTON TYROSINE KINASE; FLUDARABINE; IBRUTINIB; OFATUMUMAB; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CELLULITIS; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; COUGHING; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HUMAN; IC 50; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84871740442     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0147-9     Document Type: Article

References (24)

1. Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009;114(10):2044-50.
2. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49-53.
3. •• Hallek, M., Fischer, K., Fingerle-Rowson, G., et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747): 1164-74. This study has established the standard of care therapy for previously untreated CLL patients.
4. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-88.
5. Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;1:110-118.
6. • Davids, MS and Brown JR: Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk Lymphoma. 2012;53(12):2362-70. This review covers the range of inhibitors of the BCR pathway which have been studied in CLL thus far, and discusses ongoing issues with their development.
7. Hendriks RW, Bredius RG, Pike-Overzet K, Staal FJ. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin Ther Targets. 2011;15(8):1003-21.
8. Wiestner, A.: Emerging role of kinase targeted strategies in chronic lymphocytic leukemia. Blood. 2012;120(24):4684-91.
9. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-80.
10. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-96.
11. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590-4.
12. Ponader S, Chen SS, Buggy JJ, et al.: Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182-1189.
13. Advani RH, Buggy JJ, Sharman JP, et al. The BTK Inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B cell malignancies: Final Results from a Phase 1 Study. J Clin Oncol. doi: 10.1200/JCO.2012.44.4281
14. Burger JA, O'Brien S, Fowler N, et al. The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): an update on ongoing phase 1 studies. ASH Annual Meeting Abstracts. 2010;116(21):57.
15. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-56.
16. • Cheson BD, Byrd JC, Rai KR, et al.: Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012, 30(23):2820-2. This article discusses the adaptation to the CLL response criteria which is required for the evaluation of the BCR pathway inhibitors.
17. O'Brien S, Burger J, Blum K, et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): follow-up of a phase Ib/II study. ASH Annual Meeting Abstracts. 2011;118(21):983.
18. Byrd JC, Furman R, Coutre S, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): interim results of a phase Ib/II study. ASCO Meeting Abstracts. 2012;30(15-suppl):6507.
19. Wierda WG, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-55.
20. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011;118(19):5126-9.
21. Jaglowski SM, Jones J, Flynn J, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. ASCO Meeting Abstracts. 2012;30(15-suppl):6508.
22. O'Brien SM, Barrientos J, Flinn I, et al. Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study. ASCO Meeting Abstracts. 2012;30(15-suppl):6515.
23. Brown JR, Barrientos J, Flinn I, et al.: The Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib combined with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL, interim results of a phase Ib/II study. EHA Meeting Abstracts 2012, 97.
24. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559-66.